nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Selegiline—CYP2A6—lung cancer	0.00198	0.238	CrCbGaD
Lisdexamfetamine—Amphetamine—CYP2A6—lung cancer	0.00165	0.198	CrCbGaD
Lisdexamfetamine—Selegiline—CYP2E1—lung cancer	0.00141	0.169	CrCbGaD
Lisdexamfetamine—Lisinopril—ABCB1—lung cancer	0.00131	0.158	CrCbGaD
Lisdexamfetamine—Phenelzine—CYP2E1—lung cancer	0.00124	0.149	CrCbGaD
Lisdexamfetamine—Anaphylactic shock—Cisplatin—lung cancer	0.00106	0.00129	CcSEcCtD
Lisdexamfetamine—Insomnia—Irinotecan—lung cancer	0.00105	0.00129	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Docetaxel—lung cancer	0.00105	0.00129	CcSEcCtD
Lisdexamfetamine—Vomiting—Topotecan—lung cancer	0.00105	0.00128	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Doxorubicin—lung cancer	0.00104	0.00128	CcSEcCtD
Lisdexamfetamine—Rash—Topotecan—lung cancer	0.00104	0.00127	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Vinorelbine—lung cancer	0.00104	0.00127	CcSEcCtD
Lisdexamfetamine—Dermatitis—Topotecan—lung cancer	0.00104	0.00127	CcSEcCtD
Lisdexamfetamine—Vomiting—Erlotinib—lung cancer	0.00104	0.00127	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Irinotecan—lung cancer	0.00104	0.00127	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Cisplatin—lung cancer	0.00104	0.00127	CcSEcCtD
Lisdexamfetamine—Somnolence—Irinotecan—lung cancer	0.00104	0.00127	CcSEcCtD
Lisdexamfetamine—Headache—Topotecan—lung cancer	0.00103	0.00126	CcSEcCtD
Lisdexamfetamine—Tachycardia—Cisplatin—lung cancer	0.00103	0.00126	CcSEcCtD
Lisdexamfetamine—Rash—Erlotinib—lung cancer	0.00103	0.00126	CcSEcCtD
Lisdexamfetamine—Dermatitis—Erlotinib—lung cancer	0.00103	0.00126	CcSEcCtD
Lisdexamfetamine—Palpitations—Paclitaxel—lung cancer	0.00103	0.00126	CcSEcCtD
Lisdexamfetamine—Convulsion—Etoposide—lung cancer	0.00103	0.00126	CcSEcCtD
Lisdexamfetamine—Skin disorder—Cisplatin—lung cancer	0.00103	0.00126	CcSEcCtD
Lisdexamfetamine—Insomnia—Gemcitabine—lung cancer	0.00103	0.00126	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Irinotecan—lung cancer	0.00103	0.00125	CcSEcCtD
Lisdexamfetamine—Hypertension—Etoposide—lung cancer	0.00102	0.00125	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Docetaxel—lung cancer	0.00102	0.00125	CcSEcCtD
Lisdexamfetamine—Headache—Erlotinib—lung cancer	0.00102	0.00125	CcSEcCtD
Lisdexamfetamine—Diplopia—Doxorubicin—lung cancer	0.00102	0.00125	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Cisplatin—lung cancer	0.00102	0.00125	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Docetaxel—lung cancer	0.00102	0.00125	CcSEcCtD
Lisdexamfetamine—Asthenia—Vinorelbine—lung cancer	0.00101	0.00124	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Irinotecan—lung cancer	0.00101	0.00124	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Gemcitabine—lung cancer	0.00101	0.00124	CcSEcCtD
Lisdexamfetamine—Nausea—Vinblastine—lung cancer	0.00101	0.00123	CcSEcCtD
Lisdexamfetamine—Somnolence—Gemcitabine—lung cancer	0.00101	0.00123	CcSEcCtD
Lisdexamfetamine—Convulsion—Paclitaxel—lung cancer	0.00101	0.00123	CcSEcCtD
Lisdexamfetamine—Anorexia—Cisplatin—lung cancer	0.00101	0.00123	CcSEcCtD
Lisdexamfetamine—Affect lability—Doxorubicin—lung cancer	0.00101	0.00123	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Irinotecan—lung cancer	0.00101	0.00123	CcSEcCtD
Lisdexamfetamine—Hypertension—Paclitaxel—lung cancer	0.001	0.00123	CcSEcCtD
Lisdexamfetamine—Fatigue—Irinotecan—lung cancer	0.001	0.00123	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.001	0.00123	CcSEcCtD
Lisdexamfetamine—Constipation—Irinotecan—lung cancer	0.000996	0.00122	CcSEcCtD
Lisdexamfetamine—Mental disorder—Docetaxel—lung cancer	0.000993	0.00121	CcSEcCtD
Lisdexamfetamine—Anxiety—Paclitaxel—lung cancer	0.000987	0.00121	CcSEcCtD
Lisdexamfetamine—Malnutrition—Docetaxel—lung cancer	0.000986	0.00121	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Gemcitabine—lung cancer	0.000986	0.00121	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000984	0.0012	CcSEcCtD
Lisdexamfetamine—Nausea—Topotecan—lung cancer	0.00098	0.0012	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000979	0.0012	CcSEcCtD
Lisdexamfetamine—Fatigue—Gemcitabine—lung cancer	0.000978	0.0012	CcSEcCtD
Lisdexamfetamine—Constipation—Gemcitabine—lung cancer	0.00097	0.00119	CcSEcCtD
Lisdexamfetamine—Nausea—Erlotinib—lung cancer	0.00097	0.00119	CcSEcCtD
Lisdexamfetamine—Dry mouth—Paclitaxel—lung cancer	0.000969	0.00119	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Etoposide—lung cancer	0.000969	0.00118	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Vinorelbine—lung cancer	0.000966	0.00118	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Paclitaxel—lung cancer	0.00095	0.00116	CcSEcCtD
Lisdexamfetamine—Tachycardia—Etoposide—lung cancer	0.000945	0.00116	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Cisplatin—lung cancer	0.000943	0.00115	CcSEcCtD
Lisdexamfetamine—Skin disorder—Etoposide—lung cancer	0.000941	0.00115	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Methotrexate—lung cancer	0.00094	0.00115	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Etoposide—lung cancer	0.000936	0.00115	CcSEcCtD
Lisdexamfetamine—Dizziness—Vinorelbine—lung cancer	0.000934	0.00114	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Doxorubicin—lung cancer	0.000934	0.00114	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Paclitaxel—lung cancer	0.000931	0.00114	CcSEcCtD
Lisdexamfetamine—Tachycardia—Paclitaxel—lung cancer	0.000927	0.00113	CcSEcCtD
Lisdexamfetamine—Anorexia—Etoposide—lung cancer	0.000923	0.00113	CcSEcCtD
Lisdexamfetamine—Skin disorder—Paclitaxel—lung cancer	0.000922	0.00113	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Irinotecan—lung cancer	0.000921	0.00113	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Doxorubicin—lung cancer	0.00092	0.00113	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Cisplatin—lung cancer	0.000919	0.00112	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Paclitaxel—lung cancer	0.000918	0.00112	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000913	0.00112	CcSEcCtD
Lisdexamfetamine—Depression—Methotrexate—lung cancer	0.000907	0.00111	CcSEcCtD
Lisdexamfetamine—Anorexia—Paclitaxel—lung cancer	0.000905	0.00111	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Methotrexate—lung cancer	0.000902	0.0011	CcSEcCtD
Lisdexamfetamine—Vomiting—Vinorelbine—lung cancer	0.000898	0.0011	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Gemcitabine—lung cancer	0.000897	0.0011	CcSEcCtD
Lisdexamfetamine—Rash—Vinorelbine—lung cancer	0.00089	0.00109	CcSEcCtD
Lisdexamfetamine—Dermatitis—Vinorelbine—lung cancer	0.000889	0.00109	CcSEcCtD
Lisdexamfetamine—Headache—Vinorelbine—lung cancer	0.000885	0.00108	CcSEcCtD
Lisdexamfetamine—Palpitations—Docetaxel—lung cancer	0.000872	0.00107	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Etoposide—lung cancer	0.000864	0.00106	CcSEcCtD
Lisdexamfetamine—Somnolence—Etoposide—lung cancer	0.000861	0.00105	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Methotrexate—lung cancer	0.00086	0.00105	CcSEcCtD
Lisdexamfetamine—Insomnia—Paclitaxel—lung cancer	0.000859	0.00105	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Irinotecan—lung cancer	0.000858	0.00105	CcSEcCtD
Lisdexamfetamine—Convulsion—Docetaxel—lung cancer	0.000855	0.00105	CcSEcCtD
Lisdexamfetamine—Hypertension—Docetaxel—lung cancer	0.000852	0.00104	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Paclitaxel—lung cancer	0.000847	0.00104	CcSEcCtD
Lisdexamfetamine—Somnolence—Paclitaxel—lung cancer	0.000844	0.00103	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Etoposide—lung cancer	0.000842	0.00103	CcSEcCtD
Lisdexamfetamine—Nausea—Vinorelbine—lung cancer	0.000839	0.00103	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Etoposide—lung cancer	0.000836	0.00102	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Paclitaxel—lung cancer	0.000836	0.00102	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Cisplatin—lung cancer	0.000836	0.00102	CcSEcCtD
Lisdexamfetamine—Asthenia—Irinotecan—lung cancer	0.000836	0.00102	CcSEcCtD
Lisdexamfetamine—Fatigue—Etoposide—lung cancer	0.000835	0.00102	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000834	0.00102	CcSEcCtD
Lisdexamfetamine—Constipation—Etoposide—lung cancer	0.000828	0.00101	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Paclitaxel—lung cancer	0.000826	0.00101	CcSEcCtD
Lisdexamfetamine—Dry mouth—Docetaxel—lung cancer	0.000821	0.001	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.00082	0.001	CcSEcCtD
Lisdexamfetamine—Fatigue—Paclitaxel—lung cancer	0.000819	0.001	CcSEcCtD
Lisdexamfetamine—Hepatitis—Methotrexate—lung cancer	0.000817	0.000999	CcSEcCtD
Lisdexamfetamine—Asthenia—Gemcitabine—lung cancer	0.000814	0.000996	CcSEcCtD
Lisdexamfetamine—Constipation—Paclitaxel—lung cancer	0.000812	0.000993	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Docetaxel—lung cancer	0.000805	0.000985	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—lung cancer	0.000804	0.000984	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—lung cancer	0.000799	0.000978	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Irinotecan—lung cancer	0.000797	0.000975	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Docetaxel—lung cancer	0.000789	0.000966	CcSEcCtD
Lisdexamfetamine—Visual impairment—Methotrexate—lung cancer	0.000787	0.000963	CcSEcCtD
Lisdexamfetamine—Tachycardia—Docetaxel—lung cancer	0.000786	0.000961	CcSEcCtD
Lisdexamfetamine—Skin disorder—Docetaxel—lung cancer	0.000782	0.000956	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—lung cancer	0.000781	0.000955	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Cisplatin—lung cancer	0.000779	0.000953	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Gemcitabine—lung cancer	0.000776	0.000949	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Methotrexate—lung cancer	0.000772	0.000945	CcSEcCtD
Lisdexamfetamine—Dizziness—Irinotecan—lung cancer	0.00077	0.000942	CcSEcCtD
Lisdexamfetamine—Urticaria—Etoposide—lung cancer	0.000769	0.000941	CcSEcCtD
Lisdexamfetamine—Anorexia—Docetaxel—lung cancer	0.000767	0.000939	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Etoposide—lung cancer	0.000766	0.000937	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methotrexate—lung cancer	0.000763	0.000934	CcSEcCtD
Lisdexamfetamine—Asthenia—Cisplatin—lung cancer	0.000759	0.000928	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methotrexate—lung cancer	0.000758	0.000927	CcSEcCtD
Lisdexamfetamine—Urticaria—Paclitaxel—lung cancer	0.000754	0.000923	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Paclitaxel—lung cancer	0.000751	0.000918	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—lung cancer	0.000745	0.000911	CcSEcCtD
Lisdexamfetamine—Vomiting—Irinotecan—lung cancer	0.00074	0.000906	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methotrexate—lung cancer	0.000738	0.000902	CcSEcCtD
Lisdexamfetamine—Selegiline—ABCB1—lung cancer	0.000737	0.0886	CrCbGaD
Lisdexamfetamine—Mediastinal disorder—Methotrexate—lung cancer	0.000736	0.0009	CcSEcCtD
Lisdexamfetamine—Rash—Irinotecan—lung cancer	0.000734	0.000898	CcSEcCtD
Lisdexamfetamine—Dermatitis—Irinotecan—lung cancer	0.000734	0.000897	CcSEcCtD
Lisdexamfetamine—Headache—Irinotecan—lung cancer	0.00073	0.000892	CcSEcCtD
Lisdexamfetamine—Insomnia—Docetaxel—lung cancer	0.000728	0.000891	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Cisplatin—lung cancer	0.000723	0.000885	CcSEcCtD
Lisdexamfetamine—Vomiting—Gemcitabine—lung cancer	0.000721	0.000882	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Docetaxel—lung cancer	0.000718	0.000878	CcSEcCtD
Lisdexamfetamine—Somnolence—Docetaxel—lung cancer	0.000716	0.000875	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methotrexate—lung cancer	0.000715	0.000875	CcSEcCtD
Lisdexamfetamine—Rash—Gemcitabine—lung cancer	0.000715	0.000875	CcSEcCtD
Lisdexamfetamine—Dermatitis—Gemcitabine—lung cancer	0.000715	0.000874	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Etoposide—lung cancer	0.000714	0.000873	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methotrexate—lung cancer	0.000711	0.00087	CcSEcCtD
Lisdexamfetamine—Headache—Gemcitabine—lung cancer	0.000711	0.000869	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Docetaxel—lung cancer	0.000709	0.000867	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—lung cancer	0.000707	0.000865	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Docetaxel—lung cancer	0.0007	0.000856	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Paclitaxel—lung cancer	0.0007	0.000856	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000695	0.00085	CcSEcCtD
Lisdexamfetamine—Asthenia—Etoposide—lung cancer	0.000695	0.00085	CcSEcCtD
Lisdexamfetamine—Fatigue—Docetaxel—lung cancer	0.000694	0.000849	CcSEcCtD
Lisdexamfetamine—Nausea—Irinotecan—lung cancer	0.000692	0.000846	CcSEcCtD
Lisdexamfetamine—Constipation—Docetaxel—lung cancer	0.000688	0.000842	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—lung cancer	0.000681	0.000834	CcSEcCtD
Lisdexamfetamine—Asthenia—Paclitaxel—lung cancer	0.000681	0.000834	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC34A2—lung cancer	0.000678	0.00389	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—GNG11—lung cancer	0.000678	0.00389	CbGpPWpGaD
Lisdexamfetamine—Nausea—Gemcitabine—lung cancer	0.000674	0.000824	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neuronal System—CHRNA5—lung cancer	0.000674	0.00387	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Cisplatin—lung cancer	0.000672	0.000822	CcSEcCtD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADCY1—lung cancer	0.000672	0.00386	CbGpPWpGaD
Lisdexamfetamine—Vision blurred—Methotrexate—lung cancer	0.00067	0.00082	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—lung cancer	0.000669	0.000818	CcSEcCtD
Lisdexamfetamine—Rash—Cisplatin—lung cancer	0.000667	0.000816	CcSEcCtD
Lisdexamfetamine—Dermatitis—Cisplatin—lung cancer	0.000666	0.000815	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—GRP—lung cancer	0.000666	0.00382	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—OXTR—lung cancer	0.000666	0.00382	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Etoposide—lung cancer	0.000663	0.000811	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—lung cancer	0.000661	0.000808	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—lung cancer	0.000656	0.000803	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Paclitaxel—lung cancer	0.00065	0.000795	CcSEcCtD
Lisdexamfetamine—Dizziness—Etoposide—lung cancer	0.000641	0.000784	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—lung cancer	0.000639	0.000781	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—lung cancer	0.000637	0.00078	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Docetaxel—lung cancer	0.000636	0.000778	CcSEcCtD
Lisdexamfetamine—Dizziness—Paclitaxel—lung cancer	0.000628	0.000768	CcSEcCtD
Lisdexamfetamine—Nausea—Cisplatin—lung cancer	0.000628	0.000768	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—GNG11—lung cancer	0.000623	0.00358	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—NQO1—lung cancer	0.00062	0.00356	CbGpPWpGaD
Lisdexamfetamine—Mental disorder—Doxorubicin—lung cancer	0.00062	0.000758	CcSEcCtD
Lisdexamfetamine—Convulsion—Methotrexate—lung cancer	0.000616	0.000753	CcSEcCtD
Lisdexamfetamine—Vomiting—Etoposide—lung cancer	0.000616	0.000753	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—lung cancer	0.000616	0.000753	CcSEcCtD
Lisdexamfetamine—Rash—Etoposide—lung cancer	0.000611	0.000747	CcSEcCtD
Lisdexamfetamine—Dermatitis—Etoposide—lung cancer	0.00061	0.000746	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—ADCY1—lung cancer	0.000609	0.0035	CbGpPWpGaD
Lisdexamfetamine—Headache—Etoposide—lung cancer	0.000607	0.000742	CcSEcCtD
Lisdexamfetamine—Vomiting—Paclitaxel—lung cancer	0.000604	0.000739	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000601	0.000735	CcSEcCtD
Lisdexamfetamine—Rash—Paclitaxel—lung cancer	0.000599	0.000733	CcSEcCtD
Lisdexamfetamine—Dermatitis—Paclitaxel—lung cancer	0.000598	0.000732	CcSEcCtD
Lisdexamfetamine—Nervousness—Doxorubicin—lung cancer	0.000598	0.000731	CcSEcCtD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—lung cancer	0.000595	0.00342	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—OXTR—lung cancer	0.000595	0.00342	CbGpPWpGaD
Lisdexamfetamine—Headache—Paclitaxel—lung cancer	0.000595	0.000728	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Docetaxel—lung cancer	0.000593	0.000726	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTP1—lung cancer	0.000583	0.00335	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A18—lung cancer	0.00058	0.00333	CbGpPWpGaD
Lisdexamfetamine—Anaphylactic shock—Methotrexate—lung cancer	0.00058	0.00071	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—lung cancer	0.00058	0.00071	CcSEcCtD
Lisdexamfetamine—Asthenia—Docetaxel—lung cancer	0.000578	0.000707	CcSEcCtD
Lisdexamfetamine—Nausea—Etoposide—lung cancer	0.000575	0.000704	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methotrexate—lung cancer	0.000569	0.000696	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—lung cancer	0.000566	0.000692	CcSEcCtD
Lisdexamfetamine—Nausea—Paclitaxel—lung cancer	0.000564	0.00069	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methotrexate—lung cancer	0.000564	0.000689	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methotrexate—lung cancer	0.000561	0.000686	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CG—lung cancer	0.00056	0.00321	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GNG11—lung cancer	0.000557	0.0032	CbGpPWpGaD
Lisdexamfetamine—Anorexia—Methotrexate—lung cancer	0.000553	0.000677	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Docetaxel—lung cancer	0.000551	0.000674	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neuronal System—CHRNA3—lung cancer	0.000549	0.00315	CbGpPWpGaD
Lisdexamfetamine—Palpitations—Doxorubicin—lung cancer	0.000544	0.000665	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTM1—lung cancer	0.000536	0.00308	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—AVP—lung cancer	0.000534	0.00307	CbGpPWpGaD
Lisdexamfetamine—Convulsion—Doxorubicin—lung cancer	0.000533	0.000652	CcSEcCtD
Lisdexamfetamine—Dizziness—Docetaxel—lung cancer	0.000532	0.000651	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—lung cancer	0.000531	0.00065	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP2—lung cancer	0.000527	0.00302	CbGpPWpGaD
Lisdexamfetamine—Insomnia—Methotrexate—lung cancer	0.000525	0.000642	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—lung cancer	0.000522	0.000639	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.00052	0.000637	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neuronal System—GNG11—lung cancer	0.000519	0.00298	CbGpPWpGaD
Lisdexamfetamine—Dyspnoea—Methotrexate—lung cancer	0.000517	0.000633	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTP1—lung cancer	0.000517	0.00297	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCC3—lung cancer	0.000517	0.00297	CbGpPWpGaD
Lisdexamfetamine—Somnolence—Methotrexate—lung cancer	0.000516	0.000631	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—OXTR—lung cancer	0.000514	0.00295	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A18—lung cancer	0.000514	0.00295	CbGpPWpGaD
Lisdexamfetamine—Dry mouth—Doxorubicin—lung cancer	0.000513	0.000627	CcSEcCtD
Lisdexamfetamine—Vomiting—Docetaxel—lung cancer	0.000512	0.000626	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methotrexate—lung cancer	0.000511	0.000625	CcSEcCtD
Lisdexamfetamine—Rash—Docetaxel—lung cancer	0.000508	0.000621	CcSEcCtD
Lisdexamfetamine—Dermatitis—Docetaxel—lung cancer	0.000507	0.00062	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Methotrexate—lung cancer	0.000504	0.000617	CcSEcCtD
Lisdexamfetamine—Headache—Docetaxel—lung cancer	0.000504	0.000617	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—lung cancer	0.000502	0.000615	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000501	0.000613	CcSEcCtD
Lisdexamfetamine—Fatigue—Methotrexate—lung cancer	0.0005	0.000612	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—lung cancer	0.000493	0.000603	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CD—lung cancer	0.000492	0.00282	CbGpPWpGaD
Lisdexamfetamine—Tachycardia—Doxorubicin—lung cancer	0.00049	0.0006	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—ANXA1—lung cancer	0.00049	0.00281	CbGpPWpGaD
Lisdexamfetamine—Skin disorder—Doxorubicin—lung cancer	0.000488	0.000597	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—lung cancer	0.000486	0.000594	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GIPR—lung cancer	0.000479	0.00275	CbGpPWpGaD
Lisdexamfetamine—Anorexia—Doxorubicin—lung cancer	0.000479	0.000586	CcSEcCtD
Lisdexamfetamine—Nausea—Docetaxel—lung cancer	0.000478	0.000585	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTM1—lung cancer	0.000475	0.00273	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—GNG11—lung cancer	0.000468	0.00269	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—ADCY1—lung cancer	0.000467	0.00268	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—APP—lung cancer	0.000464	0.00266	CbGpPWpGaD
Lisdexamfetamine—Urticaria—Methotrexate—lung cancer	0.000461	0.000564	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Methotrexate—lung cancer	0.000459	0.000561	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—PIK3CB—lung cancer	0.000455	0.00261	CbGpPWpGaD
Lisdexamfetamine—Insomnia—Doxorubicin—lung cancer	0.000454	0.000556	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Doxorubicin—lung cancer	0.000448	0.000548	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—lung cancer	0.000447	0.000546	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Doxorubicin—lung cancer	0.000442	0.000541	CcSEcCtD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—GRP—lung cancer	0.000441	0.00253	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—OXTR—lung cancer	0.000441	0.00253	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—lung cancer	0.000438	0.00251	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CXCL8—lung cancer	0.000438	0.00251	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Doxorubicin—lung cancer	0.000437	0.000534	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000434	0.000531	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—lung cancer	0.000433	0.00053	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—BRAF—lung cancer	0.000432	0.00248	CbGpPWpGaD
Lisdexamfetamine—Constipation—Doxorubicin—lung cancer	0.00043	0.000526	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CB—lung cancer	0.000429	0.00246	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—MTOR—lung cancer	0.000429	0.00246	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Methotrexate—lung cancer	0.000427	0.000523	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ADCY1—lung cancer	0.000421	0.00242	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCG2—lung cancer	0.000421	0.00242	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CASP3—lung cancer	0.000419	0.0024	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Methotrexate—lung cancer	0.000416	0.000509	CcSEcCtD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—APP—lung cancer	0.000415	0.00238	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GRM8—lung cancer	0.000408	0.00234	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—JUN—lung cancer	0.000407	0.00234	CbGpPWpGaD
Lisdexamfetamine—Urticaria—Doxorubicin—lung cancer	0.000399	0.000488	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Doxorubicin—lung cancer	0.000397	0.000486	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methotrexate—lung cancer	0.000397	0.000486	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP9—lung cancer	0.000396	0.00227	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—TF—lung cancer	0.000392	0.00225	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Methotrexate—lung cancer	0.000384	0.000469	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—CDKN1A—lung cancer	0.000371	0.00213	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—lung cancer	0.00037	0.000453	CcSEcCtD
Lisdexamfetamine—Vomiting—Methotrexate—lung cancer	0.000369	0.000451	CcSEcCtD
Lisdexamfetamine—Rash—Methotrexate—lung cancer	0.000366	0.000448	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methotrexate—lung cancer	0.000365	0.000447	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—SRC—lung cancer	0.000365	0.00209	CbGpPWpGaD
Lisdexamfetamine—Headache—Methotrexate—lung cancer	0.000363	0.000445	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—MDM2—lung cancer	0.000362	0.00208	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—RAF1—lung cancer	0.000361	0.00207	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—AVP—lung cancer	0.000361	0.00207	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Doxorubicin—lung cancer	0.00036	0.000441	CcSEcCtD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—AVP—lung cancer	0.000359	0.00206	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCC3—lung cancer	0.000348	0.002	CbGpPWpGaD
Lisdexamfetamine—Nausea—Methotrexate—lung cancer	0.000345	0.000422	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Doxorubicin—lung cancer	0.000344	0.00042	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GRP—lung cancer	0.000336	0.00193	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—OXTR—lung cancer	0.000336	0.00193	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Doxorubicin—lung cancer	0.000332	0.000406	CcSEcCtD
Lisdexamfetamine—SLC18A2—Neuronal System—BRAF—lung cancer	0.000331	0.0019	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ANXA1—lung cancer	0.000324	0.00186	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—lung cancer	0.000324	0.00186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—lung cancer	0.000323	0.00185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—EGFR—lung cancer	0.00032	0.00184	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Doxorubicin—lung cancer	0.000319	0.000391	CcSEcCtD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—AVP—lung cancer	0.000318	0.00183	CbGpPWpGaD
Lisdexamfetamine—Rash—Doxorubicin—lung cancer	0.000317	0.000387	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—lung cancer	0.000316	0.000387	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—GNG11—lung cancer	0.000315	0.00181	CbGpPWpGaD
Lisdexamfetamine—Headache—Doxorubicin—lung cancer	0.000315	0.000385	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GNG11—lung cancer	0.000314	0.0018	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCC3—lung cancer	0.000308	0.00177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—APP—lung cancer	0.000307	0.00176	CbGpPWpGaD
Lisdexamfetamine—Nausea—Doxorubicin—lung cancer	0.000298	0.000365	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ADCY1—lung cancer	0.000283	0.00163	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCG2—lung cancer	0.000283	0.00163	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GNG11—lung cancer	0.000279	0.0016	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—MDM2—lung cancer	0.000278	0.00159	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—RAF1—lung cancer	0.000277	0.00159	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—AVP—lung cancer	0.000271	0.00156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GIPR—lung cancer	0.000271	0.00155	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—TF—lung cancer	0.000263	0.00151	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000263	0.00151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PTHLH—lung cancer	0.000263	0.00151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CA—lung cancer	0.000261	0.0015	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—lung cancer	0.000258	0.00148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—HRAS—lung cancer	0.000257	0.00147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—lung cancer	0.000253	0.00145	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ADCY1—lung cancer	0.000251	0.00144	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCG2—lung cancer	0.000251	0.00144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ANXA1—lung cancer	0.000247	0.00142	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GIPR—lung cancer	0.000246	0.00141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—lung cancer	0.000244	0.0014	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.000239	0.00137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—APP—lung cancer	0.000234	0.00134	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TF—lung cancer	0.000233	0.00134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRM8—lung cancer	0.00023	0.00132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—lung cancer	0.000227	0.0013	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—lung cancer	0.000218	0.00125	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MDM2—lung cancer	0.000216	0.00124	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—RAF1—lung cancer	0.000215	0.00124	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—lung cancer	0.000214	0.00123	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—lung cancer	0.000209	0.0012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRM8—lung cancer	0.000209	0.0012	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—APOA1—lung cancer	0.000208	0.00119	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—lung cancer	0.000199	0.00114	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—lung cancer	0.000199	0.00114	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BRAF—lung cancer	0.000197	0.00113	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—lung cancer	0.000193	0.00111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AXL—lung cancer	0.000192	0.0011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—OXTR—lung cancer	0.00019	0.00109	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRP—lung cancer	0.00019	0.00109	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—AVP—lung cancer	0.000183	0.00105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AVP—lung cancer	0.000182	0.00105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNG11—lung cancer	0.000178	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—lung cancer	0.000177	0.00102	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000177	0.00102	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000176	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OXTR—lung cancer	0.000172	0.000989	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRP—lung cancer	0.000172	0.000989	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MDM2—lung cancer	0.000165	0.00095	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—RAF1—lung cancer	0.000165	0.000946	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—lung cancer	0.000164	0.000944	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—AVP—lung cancer	0.000162	0.000929	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNG11—lung cancer	0.000161	0.000926	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADCY1—lung cancer	0.00016	0.000916	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000159	0.000912	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000157	0.000899	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—HRAS—lung cancer	0.000152	0.000874	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—COL4A2—lung cancer	0.000149	0.000856	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—RAF1—lung cancer	0.000149	0.000854	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PTHLH—lung cancer	0.000148	0.000852	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GIPR—lung cancer	0.000145	0.000834	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADCY1—lung cancer	0.000145	0.000832	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PPP2R1B—lung cancer	0.000141	0.000811	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—APOA1—lung cancer	0.00014	0.000802	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ANXA1—lung cancer	0.00014	0.000801	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SDC4—lung cancer	0.000136	0.000779	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTHLH—lung cancer	0.000135	0.000774	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—lung cancer	0.000133	0.000764	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DUSP3—lung cancer	0.000133	0.000763	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—APP—lung cancer	0.000132	0.000759	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RHEB—lung cancer	0.00013	0.000748	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—lung cancer	0.000128	0.000732	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ANXA1—lung cancer	0.000127	0.000727	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—APOA1—lung cancer	0.000124	0.00071	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRM8—lung cancer	0.000124	0.000709	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000123	0.000705	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—lung cancer	0.000121	0.000696	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—POMC—lung cancer	0.000121	0.000694	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—APP—lung cancer	0.00012	0.00069	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SKI—lung cancer	0.00012	0.000687	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—lung cancer	0.000118	0.00068	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000118	0.000679	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—lung cancer	0.000118	0.000676	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—lung cancer	0.000115	0.000658	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—lung cancer	0.000111	0.000635	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—lung cancer	0.000105	0.000604	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000105	0.000601	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PXN—lung cancer	0.000104	0.000597	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AVP—lung cancer	0.000103	0.000591	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRP—lung cancer	0.000102	0.000584	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKR1C1—lung cancer	0.000102	0.000584	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OXTR—lung cancer	0.000102	0.000584	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—lung cancer	0.0001	0.000574	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—lung cancer	9.8e-05	0.000563	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—lung cancer	9.74e-05	0.000559	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNG11—lung cancer	9.52e-05	0.000547	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL8—lung cancer	9.36e-05	0.000537	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AVP—lung cancer	9.34e-05	0.000536	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—lung cancer	9.32e-05	0.000535	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—HRAS—lung cancer	9.08e-05	0.000521	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFC—lung cancer	9.07e-05	0.000521	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—lung cancer	8.86e-05	0.000509	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADCY1—lung cancer	8.56e-05	0.000492	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPP2R1B—lung cancer	8.35e-05	0.000479	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SMARCA4—lung cancer	8.35e-05	0.000479	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HSPB1—lung cancer	8.05e-05	0.000462	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTHLH—lung cancer	7.96e-05	0.000457	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ANXA1—lung cancer	7.49e-05	0.00043	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FLT1—lung cancer	7.25e-05	0.000416	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—lung cancer	7.18e-05	0.000412	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH3—lung cancer	7.1e-05	0.000407	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APP—lung cancer	7.1e-05	0.000407	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF9—lung cancer	7.04e-05	0.000404	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—POMC—lung cancer	6.84e-05	0.000392	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUNB—lung cancer	6.72e-05	0.000386	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—lung cancer	6.52e-05	0.000374	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CD—lung cancer	6.31e-05	0.000362	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—POMC—lung cancer	6.21e-05	0.000356	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STK11—lung cancer	6.1e-05	0.00035	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6R—lung cancer	6.06e-05	0.000348	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FOXO3—lung cancer	5.89e-05	0.000338	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAP2K1—lung cancer	5.77e-05	0.000331	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CD—lung cancer	5.73e-05	0.000329	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AVP—lung cancer	5.52e-05	0.000317	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CB—lung cancer	5.5e-05	0.000316	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1R—lung cancer	5.31e-05	0.000305	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL8—lung cancer	5.29e-05	0.000304	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HES1—lung cancer	5.22e-05	0.0003	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RAF1—lung cancer	5.12e-05	0.000294	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2—lung cancer	5.05e-05	0.00029	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CB—lung cancer	5e-05	0.000287	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL8—lung cancer	4.8e-05	0.000276	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB3—lung cancer	4.77e-05	0.000274	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2—lung cancer	4.59e-05	0.000263	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TERT—lung cancer	4.57e-05	0.000263	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGFR1—lung cancer	4.44e-05	0.000255	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIF1A—lung cancer	4.37e-05	0.000251	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOA1—lung cancer	4.22e-05	0.000242	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KDR—lung cancer	4.18e-05	0.00024	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—lung cancer	3.85e-05	0.000221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KIT—lung cancer	3.85e-05	0.000221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APC—lung cancer	3.85e-05	0.000221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NRAS—lung cancer	3.85e-05	0.000221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGF—lung cancer	3.81e-05	0.000219	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK3—lung cancer	3.69e-05	0.000212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—POMC—lung cancer	3.67e-05	0.000211	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BRAF—lung cancer	3.62e-05	0.000208	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6R—lung cancer	3.58e-05	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CREBBP—lung cancer	3.57e-05	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—lung cancer	3.51e-05	0.000202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAP2K1—lung cancer	3.41e-05	0.000196	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CD—lung cancer	3.39e-05	0.000194	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—lung cancer	3.35e-05	0.000193	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—lung cancer	3.32e-05	0.00019	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—lung cancer	3.05e-05	0.000175	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MDM2—lung cancer	3.03e-05	0.000174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RAF1—lung cancer	3.02e-05	0.000174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB2—lung cancer	2.99e-05	0.000172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTOR—lung cancer	2.95e-05	0.000169	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CB—lung cancer	2.95e-05	0.000169	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL8—lung cancer	2.84e-05	0.000163	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRAS—lung cancer	2.82e-05	0.000162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—lung cancer	2.74e-05	0.000157	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—lung cancer	2.72e-05	0.000156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2—lung cancer	2.71e-05	0.000156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—lung cancer	2.7e-05	0.000155	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—lung cancer	2.64e-05	0.000152	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUN—lung cancer	2.64e-05	0.000151	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—lung cancer	2.57e-05	0.000147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	2.56e-05	0.000147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTEN—lung cancer	2.55e-05	0.000146	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—lung cancer	2.49e-05	0.000143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EP300—lung cancer	2.43e-05	0.00014	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SRC—lung cancer	2.37e-05	0.000136	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—lung cancer	2.3e-05	0.000132	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—lung cancer	2.28e-05	0.000131	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NRAS—lung cancer	2.28e-05	0.000131	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK3—lung cancer	2.18e-05	0.000125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—lung cancer	2.12e-05	0.000122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—lung cancer	2.07e-05	0.000119	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—lung cancer	1.96e-05	0.000112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	1.8e-05	0.000103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—lung cancer	1.74e-05	9.99e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRAS—lung cancer	1.67e-05	9.56e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—lung cancer	1.59e-05	9.15e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—lung cancer	1.47e-05	8.44e-05	CbGpPWpGaD
